ChemoCentryx, Inc. (CCXI) EPS Estimated At $-0.25

October 13, 2018 - By Ellis Scott

ChemoCentryx, Inc. (NASDAQ:CCXI) LogoInvestors sentiment increased to 1.59 in 2018 Q2. Its up 0.59, from 1 in 2018Q1. It improved, as 11 investors sold ChemoCentryx, Inc. shares while 28 reduced holdings. 28 funds opened positions while 34 raised stakes. 26.37 million shares or 8.85% more from 24.22 million shares in 2018Q1 were reported.
Royal Retail Bank Of Canada accumulated 12 shares. Farallon Capital Mngmt Limited Liability Company has invested 0.09% in ChemoCentryx, Inc. (NASDAQ:CCXI). Wasatch Advisors owns 0.38% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 2.38M shares. Prudential Incorporated holds 10,380 shares or 0% of its portfolio. Acadian Asset Mgmt Lc reported 743,298 shares or 0.04% of all its holdings. Tower Cap Lc (Trc) holds 0% or 6,793 shares in its portfolio. Bancorporation Of Mellon Corp reported 118,778 shares. Northern Tru has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Fernwood Investment Mgmt Ltd Company has 10,000 shares. Balyasny Asset Ltd Llc invested in 11,125 shares or 0% of the stock. Tiaa Cref Management Ltd Liability Corporation stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Dimensional Fund Advsrs Lp stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Manufacturers Life Insurance Co The has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Nantahala Cap Mgmt Llc invested in 0.33% or 615,173 shares. Int Grp reported 14,278 shares.

Since May 1, 2018, it had 0 insider purchases, and 12 selling transactions for $7.89 million activity. Another trade for 2,709 shares valued at $35,217 was sold by Cappel Markus J.. Another trade for 10,857 shares valued at $152,028 was sold by Schall Thomas J..

Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.25 EPS on November, 6.They anticipate $0.12 EPS change or 92.31 % from last quarter’s $-0.13 EPS. After having $-0.14 EPS previously, ChemoCentryx, Inc.’s analysts see 78.57 % EPS growth. The stock increased 2.20% or $0.22 during the last trading session, reaching $10.24. About 82,230 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 51.30% since October 13, 2017 and is uptrending. It has outperformed by 35.68% the S&P500.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

Among 5 analysts covering ChemoCentryx (NASDAQ:CCXI), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. ChemoCentryx had 5 analyst reports since May 2, 2018 according to SRatingsIntel. On Tuesday, August 14 the stock rating was downgraded by JP Morgan to “Neutral”.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $515.88 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 30.57 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn's diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx Announces Proposed Public Offering of Common Stock” on September 26, 2018, also Nasdaq.com with their article: “ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference” published on September 26, 2018, Seekingalpha.com published: “ChemoCentryx terminates previously announced common stock offering” on September 28, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “Mid-Morning Market Update: Markets Open Higher; Conagra Misses Q1 Views” published on September 27, 2018 as well as Nasdaq.com‘s news article titled: “Mid-Day Market Update: Crude Oil Up 1.5%; Altimmune Shares Plunge” with publication date: September 28, 2018.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>